CAT-09-833 / Catalent - LARVOL DELTA

Catalent’s SMARTag ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego (Businesswire) - "The company announced preclinical efficacy and tolerability data demonstrating the potential of CAT-09-833, a SMARTag ADC targeting MUC1, for the treatment of platinum-resistant ovarian cancer. The company also introduced SMARTag Enhanced Conjugates, a new class of ADCs that combines different payload types to benefit more patients by amplifying efficacy without compromising safety."

Platinum resistant • Preclinical • Ovarian Cancer